CORRECTION: Sequenom's Q3 Revenues Drop 20 Percent as Net Loss Swells 43 Percent | GenomeWeb

This article has been corrected from an earlier version that said that Sequenom had "shelved" its SEQure Dx test following an investigation into mishandled data. The firm is continuing development of the test.

NEW YORK (GenomeWeb News) – Sequenom said after the market closed today that its third-quarter revenues dropped 20 percent while its net loss increased 43 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.